Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by investor765on Feb 08, 2018 3:59pm
75 Views
Post# 27529087

any words from CEO

any words from CEO


I've sent 2 emails this week and still no asnwer. Does anyone have been able to speak with the CEO ? I think a company update would be welcome from a lot of investors.

- Trial with Bayer ?
- Canadian / USA contract ?
- burn rate ? need a new Private Placement ?
- Exit of insiders (Renaud and Dundee) ? reason why ?
- IR strategy with Arrowhead deployed ? New corporate investors in sight ?
- Revenus forecast still on track ?

We don't hear much from them and most of  the time I do not get a reply back from emails.

Communication with investors and IR strategy is AS IMPORTANT AS product for junior companies. YES we have a great product, but without a good IR strategy the word will not spread out, hence more PP, more dilution. SP idle for 12 months (if not negative) .... hard to stay onboard.

Full disclosure : bought in Feb 2017. sold 50% of my shares this Summer at even (0.13).

Bullboard Posts